Literature DB >> 12393067

Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis.

Salvatore Cuzzocrea1, Prabal K Chatterjee, Emanuela Mazzon, Michelle C McDonald, Laura Dugo, Rosanna Di Paola, Ivana Serraino, Domenico Britti, Achille P Caputi, Christoph Thiemermann.   

Abstract

The aim of this study was to investigate the role of inducible nitric oxide synthase (iNOS) on the modulation of the inflammatory response in mice subjected to collagen-induced arthritis. Collagen-induced arthritis was induced in wild-type mice (iNOS-WT) treated with GW274150, a novel, potent and selective inhibitor of iNOS activity, and in mice lacking the gene for iNOS (iNOS 'knock-out', iNOS-KO), by an intradermal injection of 100 microl of emulsion containing 100 microg of bovine type II collagen and complete Freund's adjuvant at the base of the tail. After 21 days, a second injection of type II collagen in complete Freund's adjuvant was administered. iNOS-WT mice developed erosive hind paw arthritis when immunised with type II collagen in complete Freund's adjuvant. Over a 35-day period, macroscopic clinical evidence of collagen-induced arthritis first appeared as periarticular erythema and oedema in the hind paws. By day 28, the incidence of collagen-induced arthritis was 100% in type II collagen-challenged iNOS-WT mice and the severity of collagen-induced arthritis progressed with radiographic evaluation revealing resorption of bone. Histopathology of collagen-induced arthritis mice demonstrated erosion of the cartilage at the joint margins. iNOS-WT mice treated with GW274150 (5 mg/kg, i.p. daily) starting at the onset of arthritis (day 23), and iNOS-KO mice showed a delay of the development of the clinical signs at days 24-35 and an improvement of the histological status in the knee and paw. Immunohistochemical analysis for nitrotyrosine and for poly(ADP-ribose) polymerase revealed positive staining in inflamed joints from type II collagen-treated iNOS-WT mice. The degree of staining for nitrotyrosine and poly(ADP-ribose) polymerase were markedly reduced in tissue sections obtained from type II collagen-treated iNOS-WT mice, who had received GW274150 and from iNOS-KO mice. Furthermore, radiographic signs of protection against bone resorption were present in the joints of iNOS-WT mice treated with GW274150 as well as in the joint from iNOS-KO mice. This study provides the first evidence that GW274150, a novel, potent and selective inhibitor of iNOS activity, attenuates the degree of chronic inflammation and tissue damage associated with collagen-induced arthritis in mice. Furthermore, these results suggest that the induction of iNOS and NO production are essential for the up-regulation of the inflammatory response during experimental collagen-induced arthritis. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393067     DOI: 10.1016/s0014-2999(02)02338-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  16 in total

1.  Shunting of prostanoid biosynthesis in microsomal prostaglandin E synthase-1 null embryo fibroblasts: regulatory effects on inducible nitric oxide synthase expression and nitrite synthesis.

Authors:  Mohit Kapoor; Fumiaki Kojima; Min Qian; Lihua Yang; Leslie J Crofford
Journal:  FASEB J       Date:  2006-10-03       Impact factor: 5.191

2.  GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo.

Authors:  Wendy K Alderton; Anthony D R Angell; Caroline Craig; John Dawson; Edward Garvey; Salvador Moncada; Jayne Monkhouse; Daryl Rees; Linda J Russell; Rachel J Russell; Sheila Schwartz; Neil Waslidge; Richard G Knowles
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

Review 3.  The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis.

Authors:  James Leiper; Manasi Nandi
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

Review 4.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

5.  Effects of GW274150, a novel and selective inhibitor of iNOS activity, in acute lung inflammation.

Authors:  Laura Dugo; Stefania Marzocco; Emanuela Mazzon; Rosanna Di Paola; Tiziana Genovese; Achille P Caputi; Salvatore Cuzzocrea
Journal:  Br J Pharmacol       Date:  2004-02-09       Impact factor: 8.739

6.  Inflammation-associated nitrotyrosination affects TCR recognition through reduced stability and alteration of the molecular surface of the MHC complex.

Authors:  Chaithanya Madhurantakam; Adil D Duru; Tatyana Sandalova; John R Webb; Adnane Achour
Journal:  PLoS One       Date:  2012-03-14       Impact factor: 3.240

7.  Inhibition of Inducible Nitric Oxide Synthase Attenuates Monosodium Urate-induced Inflammation in Mice.

Authors:  Tae-Jin Ju; Jin-Myoung Dan; Young-Je Cho; So-Young Park
Journal:  Korean J Physiol Pharmacol       Date:  2011-12-27       Impact factor: 2.016

8.  Molecular hydrogen protects chondrocytes from oxidative stress and indirectly alters gene expressions through reducing peroxynitrite derived from nitric oxide.

Authors:  Teruyasu Hanaoka; Naomi Kamimura; Takashi Yokota; Shinro Takai; Shigeo Ohta
Journal:  Med Gas Res       Date:  2011-08-04

9.  Pharmacological or genetic inhibition of iNOS prevents cachexia-mediated muscle wasting and its associated metabolism defects.

Authors:  Jason Sadek; Derek T Hall; Bianca Colalillo; Amr Omer; Anne-Marie K Tremblay; Virginie Sanguin-Gendreau; William Muller; Sergio Di Marco; Marco Emilio Bianchi; Imed-Eddine Gallouzi
Journal:  EMBO Mol Med       Date:  2021-06-07       Impact factor: 12.137

Review 10.  Arginine-based inhibitors of nitric oxide synthase: therapeutic potential and challenges.

Authors:  Jan Víteček; Antonín Lojek; Giuseppe Valacchi; Lukáš Kubala
Journal:  Mediators Inflamm       Date:  2012-09-04       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.